ABVC BioPharma (ABVC) Stock Chart & Stock Price History → America’s worst nightmare? (From Porter & Company) (Ad) Free ABVC Stock Alerts $1.08 +0.01 (+0.93%) (As of 05/14/2024 ET) Add Compare Share Share ChartStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media ABVC BioPharma Stock Price Performance5 Day Performance+1.89%1 Month Performance-0.92%3 Month Performance-15.63%6 Month Performance-13.60%Year-To-Date Performance-6.90%1 Year Performance-86.15% Receive ABVC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ABVC BioPharma and its competitors with MarketBeat's FREE daily newsletter Email Address Ad Stocks NewsWith revenue forecasted to grow dramatically in 2024 and beyond, this company should be on your radarRevolutionizing communication is what this NASDAQ-traded next-gen solution provider is doing. See how this company is well-positioned to capitalize in 2024 ABVC Stock Chart for Wednesday, May, 15, 2024 ABVC Chart by TradingView ABVC BioPharma Share Price History Daily Weekly Monthly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year Time Frame * Start Date * End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization05/14/2024$1.07$1.08+0.93%$1.09$1.05242,038 shs$11.41 million05/13/2024$1.06$1.07+0.94%$1.14$1.06186,737 shs$11.30 million05/10/2024$1.10$1.06-3.64%$1.09$1.05206,638 shs$11.19 million05/09/2024$1.11$1.10-0.90%$1.24$1.061.31 million shs$11.62 million05/08/2024$1.06$1.11+4.72%$1.13$1.04553,806 shs$11.72 million05/07/2024$1.08$1.06-1.85%$1.08$1.03259,997 shs$11.19 million Get the Latest News and Ratings for ABVC and Related StocksEnter your email address below to receive the latest news and analysts' ratings for ABVC BioPharma and its competitors with MarketBeat's FREE daily newsletter. 05/06/2024$1.08$1.08$1.09$1.03735,481 shs$11.41 million05/03/2024$1.15$1.08-6.09%$1.15$1.07413,386 shs$11.41 million05/02/2024$1.13$1.15+1.77%$1.17$1.10308,204 shs$12.14 million05/01/2024$1.25$1.13-9.60%$1.23$1.05980,321 shs$11.93 million04/30/2024$1.40$1.25-10.71%$1.40$1.25752,769 shs$13.20 million04/29/2024$1.42$1.40-1.41%$1.45$1.301.74 million shs$14.78 million04/26/2024$1.59$1.42-10.69%$1.57$1.402.02 million shs$15.00 million04/25/2024$1.48$1.59+7.43%$1.73$1.365.33 million shs$16.79 million04/24/2024$1.35$1.48+9.63%$1.50$1.286.45 million shs$15.63 million04/23/2024$1.04$1.35+29.81%$1.37$1.007.67 million shs$14.26 million04/22/2024$0.99$1.04+5.04%$1.04$0.94307,916 shs$10.98 million04/19/2024$1.05$0.99-5.70%$1.04$0.97167,634 shs$10.46 million04/18/2024$1.02$1.05+2.94%$1.07$0.94459,059 shs$11.09 million04/17/2024$1.12$1.02-8.93%$1.19$1.001.78 million shs$10.77 million04/16/2024$1.09$1.12+2.75%$1.13$1.05109,769 shs$11.83 million04/15/2024$1.09$1.09$1.11$1.05218,100 shs$11.51 million04/12/2024$1.15$1.09-5.22%$1.15$1.08222,465 shs$11.51 million04/11/2024$1.14$1.15+0.88%$1.17$1.10265,141 shs$12.14 million04/10/2024$1.18$1.14-3.39%$1.30$1.063.78 million shs$12.04 million04/09/2024$1.25$1.18-5.60%$1.26$1.17249,003 shs$12.46 million04/08/2024$1.27$1.25-1.57%$1.31$1.25156,549 shs$13.20 million04/05/2024$1.28$1.27-0.78%$1.30$1.2567,591 shs$13.41 million04/04/2024$1.29$1.28-0.78%$1.31$1.25114,803 shs$13.52 million04/03/2024$1.29$1.29$1.30$1.24126,235 shs$13.62 million04/02/2024$1.37$1.29-5.84%$1.35$1.25202,976 shs$13.62 million04/01/2024$1.31$1.37+4.58%$1.41$1.28645,232 shs$14.47 million03/29/2024$1.31$1.31$1.31$1.16678,552 shs$13.83 million03/28/2024$1.20$1.31+9.17%$1.31$1.16670,304 shs$13.83 million03/27/2024$1.28$1.20-6.25%$1.33$1.181.43 million shs$12.67 million03/26/2024$1.05$1.28+21.90%$1.45$1.1527.15 million shs$13.52 million03/25/2024$1.07$1.05-1.87%$1.06$1.03106,302 shs$11.09 million03/22/2024$1.06$1.07+0.94%$1.08$1.0662,105 shs$8.28 million03/21/2024$1.08$1.06-1.85%$1.11$1.0683,561 shs$8.20 million03/20/2024$1.12$1.08-3.57%$1.13$1.06190,875 shs$8.36 millionAmerica’s worst nightmare? (Ad)What This Group Has Planned for the 2024 Election Will Shock You Controversial new exposé reveals what’s really going on in America, what it means for your money, and what you must do to protect your assets before it’s too late.Click here to watch this bombshell exposé now.03/19/2024$1.16$1.12-3.45%$1.17$1.10108,502 shs$8.67 million03/18/2024$1.17$1.16-0.85%$1.18$1.1464,098 shs$8.98 million03/15/2024$1.20$1.17-2.50%$1.22$1.17127,997 shs$9.06 million03/14/2024$1.23$1.20-2.44%$1.25$1.2064,665 shs$9.29 million03/13/2024$1.26$1.23-2.38%$1.25$1.2176,848 shs$9.52 million03/12/2024$1.22$1.26+3.28%$1.29$1.2159,771 shs$9.76 million03/11/2024$1.25$1.22-2.40%$1.26$1.2271,572 shs$9.44 million03/08/2024$1.25$1.25$1.29$1.2455,751 shs$9.68 million03/07/2024$1.24$1.25+0.81%$1.26$1.2139,513 shs$9.60 million03/06/2024$1.21$1.24+2.48%$1.25$1.2085,387 shs$9.60 million03/05/2024$1.24$1.21-2.42%$1.25$1.2059,411 shs$9.37 million03/04/2024$1.18$1.24+5.08%$1.27$1.19148,854 shs$9.60 million03/01/2024$1.21$1.18-2.48%$1.22$1.15135,775 shs$9.13 million02/29/2024$1.22$1.21-0.41%$1.23$1.1893,283 shs$9.37 million02/28/2024$1.23$1.22-1.22%$1.24$1.2193,737 shs$9.40 million02/27/2024$1.24$1.23-0.81%$1.25$1.2259,773 shs$9.53 million02/26/2024$1.20$1.24+3.33%$1.25$1.1880,883 shs$9.60 million02/23/2024$1.21$1.20-0.83%$1.21$1.1678,389 shs$9.29 million02/22/2024$1.19$1.21+1.68%$1.27$1.1746,426 shs$9.37 million02/21/2024$1.20$1.19-0.83%$1.21$1.15142,041 shs$9.21 million02/20/2024$1.27$1.20-5.51%$1.28$1.19167,158 shs$9.29 million02/19/2024$1.27$1.27$1.29$1.25176,900 shs$9.83 million02/16/2024$1.28$1.27-0.78%$1.29$1.25176,180 shs$9.83 million02/15/2024$1.26$1.28+1.59%$1.32$1.24291,801 shs$9.91 million02/14/2024$1.32$1.26-4.55%$1.33$1.26168,846 shs$9.75 million Related Companies: Elevai Labs Stock Chart Akari Therapeutics Stock Chart Eterna Therapeutics Stock Chart Avalo Therapeutics Stock Chart MIRA Pharmaceuticals Stock Chart Moleculin Biotech Stock Chart Molecular Templates Stock Chart Kiora Pharmaceuticals Stock Chart Guardion Health Sciences Stock Chart Monopar Therapeutics Stock Chart Receive ABVC Stock News and Ratings via EmailSign-up to receive the latest news and ratings for ABVC BioPharma and its competitors with MarketBeat's FREE daily newsletter. This page (NASDAQ:ABVC) was last updated on 5/15/2024 by MarketBeat.com Staff From Our PartnersTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaWith revenue forecasted to grow dramatically in 2024 and beyond, this company should be on your radarStocks NewsCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersCharles Payne Demystifies OptionsUnstoppable ProsperityThe A.I. story nobody is telling you (Read ASAP)TradeSmithBuy this small stock before coming AI Tidal WaveChaikin AnalyticsRevolutionizing the Green Energy Space and Building Shareholder Value Along the WaySmall Cap Sniper Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ABVC BioPharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.